Ar­gos’ PhI­II for its per­son­al­ized can­cer vac­cine im­plodes dur­ing an in­ter­im analy­sis

Ar­gos Ther­a­peu­tics’ $ARGS Phase III study of its per­son­al­ized can­cer vac­cine ro­ca­pulden­cel-T has end­ed in dis­as­ter. Its in­de­pen­dent mon­i­tor­ing com­mit­tee con­clud­ed in an in­ter­im …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER